Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Melanoma 6Leukemia, Myeloid, Acute 4Uveal Melanoma 2Lymphoma 2Leukemia 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Select Advanced Solid Tumors 1Recurrence 1Rectal Neoplasms 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Neuroblastoma 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Meningeal Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lung Neoplasms 1Leukemia, Myeloid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Neoplasms 1Kidney Diseases 1Gastrointestinal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1

Interventions

venetoclax 28Rituximab 22ibrutinib 21acalabrutinib 21Cyclophosphamide 20Specimen Handling 18obinutuzumab 15Biopsy 14fludarabine 13zanubrutinib 10pirtobrutinib 10fludarabine phosphate 9Magnetic Resonance Spectroscopy 8Bendamustine Hydrochloride 8idelalisib 6Whole-Body Irradiation 6Mycophenolic Acid 6Lenalidomide 6CT-P10 6ARQ531 6Cyclosporine 5Sirolimus 4Peripheral Blood Stem Cell Transplantation 4pembrolizumab 3Vincristine 3Tacrolimus 3Prednisone 3Doxorubicin 3Disulfides 3Cyclosporins 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Lymphocytic, Chronic, B-Cell × Interleukin-2 × 90 days × Clear all
NCT04629729 2026-03-19

FT819 in Subjects With B-cell Malignancies

Fate Therapeutics

Phase 1 Active not recruiting
54 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡